Trial Search Results
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
Stanford University
Collaborator: National Institutes of Health (NIH)
Stanford Investigator(s):
Intervention(s):
- Procedure: ablative allogeneic hematopoietic cell transplantation
Phase:
Phase 2
Eligibility
Inclusion Criteria:Morphologically confirmed relapsed non-Hodgkin's lymphoma
Age: >18 and <61 years of age
Signed informed consent Exclusion Criteria:Hepatic dysfunction defined by serum
transaminases >2.5X normal values
Serum creatinine of > 2 mg/dl or creatinine clearance < 60 ml/min
Diseases other than non-Hodgkin's lymphoma
Prior bone marrow transplant procedure
Severe psychological or medical illness
Ages Eligible for Study
18 Years - 61 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
6507230822
Not Recruiting